Overview
- Lilly’s shares rose about 1.6% on Friday, lifting its market capitalization to roughly $1 trillion and placing it among the world’s most valuable companies.
- In the latest quarter, total revenue reached $17.6 billion, with about $10.09 billion—roughly 57%—coming from obesity and diabetes treatments.
- Mounjaro generated $6.52 billion and Zepbound $3.59 billion in quarterly sales, reflecting triple‑digit year‑over‑year growth for both products.
- The stock has climbed more than 75% since Zepbound’s 2023 debut and roughly 36% this year, far outpacing broader U.S. equity benchmarks.
- Lilly says it plans to seek FDA approval for its oral GLP‑1 pill, orforglipron, by year‑end, with coverage reporting potential 2026 availability if approved, as competition intensifies from Novo Nordisk and Pfizer’s Metsera acquisition.